ClinicalTrials.gg
Not yet recruitingNCT07486167ILOCO-CHDUpdated Oct 15, 2026

Influence of Lung Volume Optimization Maneuver on Cardiac Output and Lung Compliance in Ventilated Children With Congenital Heart Disease Undergoing Surgical Repair

A Phase 1/2 interventional study of End-expiratory lung volume optimization maneuver with PEEP titration and Standard Care (in control arm) in Congenital Heart Disease, Cardiopulmonary Bypass and Mechanical Ventilation, sponsored by Charite University, Berlin, Germany. Not yet recruiting at 1 site in Germany. Open to participants aged 0 Days to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Charite University, Berlin, Germany · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 15, 2026Start date movedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
0 Days to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Heart Defects, Congenital with a site in Germany — 15 open to participants now, 15 under way, none of them phase 3. Heart Defects, Congenital · Germany.

Planned enrollment
9th of 24
80 · median 70
Started
2027
the only one that year
Phase 1/2
2 of 38
2 open now
Primary completion
2028-12
later than 9 of 14 live
Registered
36th of 38
by date
Lead sponsor
5 of 38
Charite University, Berlin, Germany

Among the 38 studies in Heart Defects, Congenital with a site in Germany, this one is the 9th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2027, is one of 2 in phase 1/2, reaches primary completion later than 9 of the 14 other live ones, and was the 36th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

15 of the 38 studies in Heart Defects, Congenital with a site in Germany are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 0 Days to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Heart Defects, Congenital with a site in Germany, or all of them as a file.
02

Study summary

The aim of this randomized interventional multi-center clinical trial is to determine whether a standardized lung volume optimization maneuver (LVOM), including PEEP titration, improves outcomes in children undergoing biventricular repair for congenital heart disease (CHD) with cardiopulmonary bypass.

The primary hypothesis is that optimizing end-expiratory lung volume through a standardized PEEP titration maneuver improves cardiac performance and lung function.

Secondary objectives are to evaluate whether this strategy reduces duration of mechanical ventilation, improves hemodynamics and ventilation-perfusion matching, and decreases the need for vasopressor support.

Read the detailed description

Cardiopulmonary bypass is associated with interruption of ventilation, leading to atelectasis, reduced end-expiratory lung volume, and increased pulmonary vascular resistance (PVR), which may impair right ventricular (RV) performance and overall cardiac output.

This study investigates whether a structured LVOM strategy can mitigate these effects by improving lung mechanics and cardiopulmonary interactions.

Specific Aims

Aim 1:

To quantify changes in hemodynamics and lung mechanics induced by LVOM under standardized postoperative (closed-chest) conditions.

Aim 2:

To compare individualized PEEP titration versus standard ventilation in terms of effects on hemodynamics and lung mechanics, while maintaining consistent tidal volume targets across groups.

Hypotheses

LVOM will improve lung mechanics and hemodynamic parameters. No significant between-group differences are expected prior to intervention. After PEEP titration, the intervention group will demonstrate superior cardiopulmonary function at moderate PEEP levels, reflecting the U-shaped relationship between lung volume and pulmonary vascular resistance (PVR).

Scientific Rationale

Cardiopulmonary bypass commonly results in atelectasis and loss of end-expiratory lung volume, contributing to increased PVR and RV afterload, with subsequent reduction in cardiac output.

Adult studies suggest that lung volume optimization through PEEP titration after CPB can improve cardiac index and RV performance. However, prospective pediatric data evaluating the interaction between ventilatory strategy, lung mechanics, and hemodynamics remain limited.

Given the central role of the right ventricle in coupling pulmonary and systemic circulation, optimizing lung volume may reduce RV afterload and improve overall cardiac performance.

Importantly, pulmonary vascular resistance follows a U-shaped relationship with lung volume, with increased resistance at both low (atelectasis) and high (overdistension) lung volumes. Individualized PEEP titration may therefore identify an optimal range that minimizes PVR while preserving hemodynamic stability.

This study addresses a critical gap by systematically evaluating cardiopulmonary interactions under contemporary ventilation strategies in pediatric cardiac surgery.

03

Conditions studied

  • Congenital Heart Disease
  • Cardiopulmonary Bypass
  • Mechanical Ventilation
  • Peep Titration in Lung Protective Ventilation
  • Positive End-expiratory Pressure (PEEP)
  • Lung Volume
  • Lung Mechanics
  • Children
  • Hemodynamic Changes
  • Cardiac Surgery

Keywords

  • cardiopulmonary interactions
  • end-expiratory lung volume
  • electrical impedance tomography
  • PEEP titration
04

Who can participate

Ages eligible
0 Days to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Inclusion Criteria
  • congenital heart disease
  • surgery with cardiopulmonary bypass

Exclusion Criteria:

  • single ventricle physiology
  • ECMO/VAD
  • \<36weeks of gestational age
  • chronic lung disease
  • Endotracheal tube leak > 15%
  • lack of from parents.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Control

    This group receives so called standard of care. This includes relatively low levels of PEEP (5cmH2O in case of planned surgery) and no standardized PEEP titration.

    Procedure: Standard Care (in control arm)

  • Experimental
    Treatment

    This group receives an individual lung volume optimization maneuver with PEEP titration. PEEP titration is performed while monitoring lung mechanics and EIT indices of overdistension and collapse and regional tidal volume distribution to optimize end-expiratory lung volume and find final "best PEEP". If possible lung perfusion will be assessed with EIT to evaluate V/Q-matching.

    Procedure: End-expiratory lung volume optimization maneuver with PEEP titration

Interventions

  • ProcedureEnd-expiratory lung volume optimization maneuver with PEEP titration

    PEEP titration (incremental/decremental) will be performed at the end of surgery to optimize lung volume and find levels of PEEP corresponding to the "best" lung compliance and "best" compromise of overdistension and collapse and "best" homogenization of tidal volume distribution assessed with EIT. PEEP levels will be applied based on individual response of patients' lung mechanics and EIT measures. Tidal volume will be kept constant at 6ml/kg in cases and controls. Driving pressures will be limited to 15cmH2O. Balance of CO2 will be guaranteed by adjusting respiratory rate.

  • ProcedureStandard Care (in control arm)

    Patients will receive pressure controlled ventilation with target tidal volume of 6ml/kg and PEEP of 5cmH2O. Driving pressures are limited to 15cmH2O. No LVOM will be applied.

06

What researchers measure

Primary outcomes

  1. Cardiac Index (L/min/BSA)

    assessed by using POCUS

    Time frame: perioperatively

Secondary outcomes

  1. lung mechanics

    lung compliance (ml/cmH2O/kg)

    Time frame: perioperatively

  2. right ventricular performance

    TAPSE PAAT Strain

    Time frame: perioperatively

  3. ventilation distribution

    EIT

    Time frame: perioperatively

  4. lung perfurision

    EIT

    Time frame: perioperatively

  5. dead space fraction

    pulmonary dead-space fraction (Vd/Vt)

    Time frame: perioperatively

  6. avDO2

    difference in arteriovenous oxygen content

    Time frame: perioperatively

07

Study locations

1 site
08

References and documents

Publications

  • "Electrical impedance tomography during open heart surgery and on the cardiac icu is feasible to monitor ventilation in children with congenital heart disease" J.-C. Clausen, M. Emeis, M. Kleine-Brueggeney, M.-Y. Cho, M. Kneyber and O. Miera Intensive Care Medicine - Paediatric and Neonatal 2024 Vol. 2 Issue 1 Pages 19 DOI: 10.1007/s44253-024-00043-4
  • Clausen JC, Emeis M, Hollander R, Miera O, Kleine-Brueggeney M, Blokpoel RGT, Garfias-Veitl T, Asendorf T, Vadiunec VV, Photiadis J, Berger F, Kneyber MCJ. Effect of Positive End-Expiratory Pressure on Cardiac Index and Right Ventricular Performance in Ventilated Children Post-Cardiac Surgery. Pediatr Crit Care Med. 2026 Feb 1;27(2):176-186. doi: 10.1097/PCC.0000000000003880. Epub 2025 Dec 19. PubMed 41416857 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: start Sep 2026 → Jan 2027, primary completion Aug 2028 → Dec 2028 and completion Dec 2028 → Jun 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Mar 20, 2026
StartEst.
Jan 1, 2027was Sep 2026
Primary completionEst.
Dec 31, 2028was Aug 2028
CompletionEst.
Jun 30, 2029was Dec 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • University Hospital Tübingen, PICU · Tübingen, Germany
Show 1 removed
  • German Heart Center of the Charité · Berlin, Germany
Oct 15, 2026
Start date
Sep 1, 2026→Jan 1, 2027
Oct 15, 2026
Primary completion
Aug 31, 2028→Dec 31, 2028
Oct 15, 2026
Study completion
Dec 31, 2028→Jun 30, 2029
Oct 15, 2026
Contact
Study contact's phone or email changed: •••2800→•••4751. See the current contact
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    1 site added, 1 site removed
    Show site
    • University Hospital Tübingen, PICU · Tübingen, Germany
    Show 1 removed
    • German Heart Center of the Charité · Berlin, Germany
    Start date Sep 1, 2026→Jan 1, 2027
    Primary completion Aug 31, 2028→Dec 31, 2028
    Study completion Dec 31, 2028→Jun 30, 2029
    Contact Study contact's phone or email changed: •••2800→•••4751. See the current contact
    + 3 other changes: identifiers, verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07486167
Responsible party
Jan Clausen, MD (Principal Investigator, University Hospital Tuebingen) — Principal investigator
First posted
Mar 20, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Oct 15, 2026

Study contacts

Jan C Clausen, MD
Contact
jan.clausen@posteo.de
004970712984751

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion